Sequence: RQIKIWFWWRRMKWKK
| Experiment Id | EXP002465 |
|---|---|
| Paper | Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Ge |
| Peptide | 89WP (penetratin derivative) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Defined via charge ratio |
| Rna Concentration | 1.5 µg siRNA per eye, 3× daily |
| Mixing Ratio | PA N/P=2:1; 89WP:siRNA=15:1 |
| Formulation Format | Topical ocular polyplex (eye drops) |
| Formulation Components | siRNA + PAMAM G3 + 89WP |
| Size Nm | 60.00 |
| Zeta Mv | 20.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Nude mouse orthotopic retinoblastoma (WERI-Rb-1-luci) |
| Administration Route | Topical instillation (eye drops) |
| Output Type | In vivo gene silencing; tumor bioluminescence |
| Output Value | Bioluminescence suppressed ~4–6× vs controls |
| Output Units | |
| Output Notes | siRNA reaches retina; functional knockdown in tumor cells |
| Toxicity Notes | Normal corneal histology; no ocular toxicity |
| Curation Notes |